Real-time ticker analysis, price-action alerts, and institutional-grade stock data.
Take-Two Interactive Software NASDAQ: TTWO reported a stronger-than-expected finish to fiscal 2026 and issued an initial fiscal 2027 outlook calling for record net bookings, driven by the planned Nov. 19 release of Grand Theft Auto VI.
Deckers Outdoor NYSE: DECK reported record fiscal 2026 revenue and earnings as growth at HOKA and UGG continued to offset a more volatile macroeconomic backdrop, with management outlining plans for high single-digit annual revenue growth through fiscal 2030.
Lionsgate Studios NYSE: LION executives said the company ended fiscal 2026 with stronger profitability, a replenished content pipeline and momentum from recent film releases, setting up what management described as significant growth in fiscal 2027 and 2028.
On May 21, 2026, HP Inc (HPQ) shares rose 3.9%, bringing the current price to $21.90. Over the past 52 weeks, the stock has experienced a high of $29.55 and a l
XRP (CRYPTO: XRP) is currently trading around $1.36 after losing the $1.40 support level on May 18. The coin is down roughly 5% over the past week, and over the last 90 days it has fallen 3.31%. Despite the ongoing recovery in Q2 2026, XRP is the only top-five crypto still in the red over... Ripple (XRP) Analysis: Why XRP Is the Only Top-5 Crypto Still in the Red Over 90 Days
Stellantis's FaSTLAne 2030's outline and new modular platform are putting this automaker under scrutiny today, May 21, 2026.
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- In a prior communication disseminated on May 21, 2026 regarding the May 29, 2026 dividend declaration for BK Class A Shares, the VWAP used to determine the payment rate was not adjusted for the May 19, 2026 Class A Share Split (1.1 for 1). Accordingly, the final dividend payable for the May 29, 2026 record date is $0.16900 per BK Class A Share, revised from the previously disclosed $0.18588. The payment rate is based on 15% of the adjusted VWAP for the last three trading days of the preceding month. The total distributions to date were impacted and have also been amended. No other changes have been made. The corrected release follows:
On May 21, 2026, Carpenter Technology Corp (CRS) shares rose 3.9% today, bringing the current price to $438.32. The stock has seen a 52-week range between $219.
On May 21, 2026, ATI Inc (ATI) shares rose by 4.3%, bringing the current price to $160.41. Over the last year, the stock has experienced significant volatility,
On May 21, 2026, West Pharmaceutical Services Inc (WST) shares rose 3.5% to $316.13. This uptick comes amidst a positive price performance, with shares having t
/PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, May 27
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
David Dietze talks about his expectations for the U.S.-Iran War and weighs uncertainty against the recent bull run led by the AI trade. He also turns to Nvidia (NVDA) following its earnings and guidance beat, outlining what the numbers mean for the greater tech sector.
CALGARY, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces voting results from its annual and special shareholders' meeting held today (the “Meeting”). A total of 39,148,743 common shares, representing approximately 83.8% of the Company's issued and outstanding common shares, were represented in person or by proxy at the Meeting.
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson's disease. Results from the study show that BIIB122 did not slow the progression of Parkinson's disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
IMAX Corp. (NYSE:IMAX) is reportedly testing buyer interest, with the company approaching entertainment firms about a potential sale, though discussions remain early and may not lead to a transaction, according to The Wall Street Journal.
Record Q1 revenue, raised 2026 guidance, and the pending SkyWater acquisition give IonQ company-specific markers to watch as federal funding headlines draw attention back to quantum computing.
London, United Kingdom--(Newsfile Corp. - May 21, 2026) - Michael J. Thomas, founder of DARWIN™ Works Marketing, has launched the iwon™ podcast (It Wasn't Over Night), a long-form series focused on the reality of building software and technology companies beyond the polished success stories often seen online.
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updates on all three of its advancing clinical programs, [²¹²Pb]VMT-α-NET, [²¹²Pb]VMT01, and [²¹²Pb]PSV359, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, IL.
BUFFALO, N.Y., May 21, 2026 /PRNewswire/ -- M&T Bank Corporation ("M&T") (NYSE:MTB) will participate in the Morgan Stanley US Financials Conference being held in New York City.
Deckers Outdoor forecast annual sales and profit above Wall Street estimates on Thursday, banking on resilient demand for its UGG boots and Hoka running shoes.
Satellogic delivers real-time Earth observation data and analytics, serving commercial and government clients across multiple industries.
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Conduent Incorporated (Nasdaq: CNDT), a global technology‑driven business solutions and services provider, today announced that it has entered into a definitive agreement to sell its Public Transit business, an operating unit of Conduent Transportation, to Modaxo, a global technology organization focused on moving the world's people. The Public Transit business consists of Transit Fare Management and Fleet Management Solutions businesses. The sale has a purc.
HOUSTON--(BUSINESS WIRE)--Halliburton Company (NYSE: HAL) announced today that its board of directors has declared a 2026 second quarter dividend of seventeen cents ($0.17) a share on the Company's common stock payable on June 24, 2026, to shareholders of record at the close of business on June 3, 2026. About Halliburton Halliburton is one of the world's leading providers of products and services to the energy industry. Founded in 1919, we create innovative technologies, products, and services.
Advanced Drainage Systems delivered strong Q4 FY2026 revenue and adjusted EPS beats, yet shares remain under pressure and valuation is approaching attractive levels. WMS's growth was fueled by the National Diversified Sales acquisition, with Stormwater and Wastewater segments both posting double-digit product line gains and rising segment profits. Despite robust operational performance, reported EPS fell due to one-time charges; adjusted EPS and net income rose, and management guides for continued revenue and EBITDA growth in FY2027.
MILL VALLEY, Calif.--(BUSINESS WIRE)--Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the acquisition of a Gerber Collision property for $3.5 million. The property is located in a highly trafficked corridor in North Carolina and corporate-operated under a triple net lease with approximately eight years of term r.
NEW YORK--(BUSINESS WIRE)--MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it will release the results of the MSCI 2026 Global Market Accessibility Review on June 18, 2026, and the results of the MSCI 2026 Annual Market Classification Review on June 23, 2026. Both announcements will be made available shortly after 10:30 p.m. Central European Summer Time (CEST) on www.msci.com/market-classificati.
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - CanCambria Energy Corp. (TSXV: CCEC) (FSE: 4JH) (OTCQB: CCEYF) ("CanCambria" or the "Company") announced today that it will participate in the 2026 Louisiana Energy Conference hosted by Al Petrie Advisors, to be held in New Orleans, Louisiana, on May 26-28, 2026, at the Four Seasons Hotel. Dr. Paul Clarke, Chief Executive Officer, will participate in an International E&P panel discussion on Wednesday, May 27, 2026, at 3:00 p.m.
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Modaxo Inc. (“Modaxo”), a global technology organization focused on moving the world's people, today announced that it has signed a definitive agreement to acquire the Public Transit Business, consisting of Transit Fare Management and Fleet Management Solutions businesses, from Conduent Incorporated. Completion of the acquisition remains subject to closing conditions.
Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years. CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026.
LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.
LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST.
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose cohorts achieved 39% ORR and 7. 3-month median PFS In the 250 mg QD 5:2 intermittent dose cohort, 50% ORR, 9.
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29 – June 2, 2026, in Chicago, Illinois. The poster, titled "Azenosertib Plus Paclitaxel for Platinum-Resistant Ovarian Cancer: Results From a Phase 1b Study," will be presented in the Gynecologic Cancer Poster Session (Abstract #5529, Poster Board #195) on June 1, 2026, from 9:00am–12:00pm CDT.
New federal quantum computing funding plans propelled this quantum specialist higher, today, May 21, 2026.
Changes Include Canada Segment, Hong Kong, AI and Data, and Technology and Operations New Team Structure Enables Execution Against Strategic Priorities for Long-term Growth TORONTO, May 21, 2026 /PRNewswire/ - Manulife has announced changes to its executive and senior leadership teams across Canada, Hong Kong, AI and Data, and Technology and Operations to enable sustainable, long-term growth as the company executes its refreshed enterprise strategy. "These important leadership changes ensure we have the right capabilities, both at the enterprise level and in our key markets of Canada and Hong Kong, to achieve our bold ambition and deliver against our new strategic priorities," said Phil Witherington, President and CEO of Manulife.
Montréal, Québec--(Newsfile Corp. - 21 mai 2026) - Amex Exploration Inc. (TSXV: AMX) (FSE: MX0) (OTCQX: AMXEF)
Zoom Communications raised its annual revenue and profit forecasts on Thursday, betting on strong demand for its AI features as the video conferencing platform looks to shore up enterprise and consumer spending.
Department of War and state officials celebrate groundbreaking in Alabama today TROY, Ala., May 21, 2026 /PRNewswire/ -- Today, Lockheed Martin broke ground on a new Munitions Production Center in Troy, Alabama, marking its latest investment to expand munitions production for the United States and its allies.
Montreal, Quebec--(Newsfile Corp. - May 21, 2026) - Amex Exploration Inc. (TSXV: AMX) (FSE: MX0) (OTCQX: AMXEF) ("Amex" or the "Company") is pleased to announce that, further to the Company's news release of earlier today, it has closed its non-brokered private placement of 1,622,222 common shares of the Company (the "Common Shares") at a price of $4.50 per Common Share (the "Offering Price") for gross proceeds of C$7,299,999 (the "Non-Brokered Private Placement"). Together with closing earlier today of the Company's "best efforts" private placement of 11,504,161 Common Shares at the Offering Price (the "Brokered Private Placement"), the Company raised aggregate gross proceeds of C$59,068,723.50.
Spot gold prices are near steady and spot silver prices are higher after the close Thursday, as lower crude oil prices and easing Treasury yields offset a firmer U.S. dollar.
Shoppers are feeling the pinch at the pump. Grocers hope to offer some relief in the produce aisle.
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
ZKH Group Limited (ZKH) Q1 2026 Earnings Call Transcript
BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatment The treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations A preliminary median progression-free survival (mPFS) of 10.3 months in the combination arm, based on early PFS analysis Activity observed across both high-grade serous and clear cell ovarian cancer subtypes Demonstrated robust Treg depletion, reprogramming of myeloid cells, and CD8+ T-cell activation, supporting BI-1808's differentiated mechanism and combination synergy with pembrolizumab Cohort expansion is underway, focusing on high-grade serous and clear cell subtypes, with another data readout expected in H2 2026 LUND, SE / ACCESS Newswire / May 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of heavily pretreated patients with advanced ovarian cancer.
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical data readouts anticipated beginning in Q1 2027 Waltham, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in progress poster of the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, will be presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, in Chicago.
RLI Corp., a dividend aristocrat, has experienced an -18% YTD stock decline, raising questions about its valuation premium. RLI maintains more than 50 years of gradual dividend increases, supplemented by regular special dividends, supporting a strong shareholder return profile. Underwriting performance remains strong, with a combined ratio below 90%, reflecting resilience in niche P&C markets.